Pharmaceutical Industry discussion, review, analysis, news and information.

According to new data presented at the annual meeting of the American Society of Regional Anesthesia and Pain Medicine, novel intranasal pain reliever of ROXRO PHARMA Inc. – ketorolac (ROX-888) - has been shown to be safe and effective in providing pain relief for patients who had undergone major surgery.

Ketorolac is a nonsteroidal anti-inflammatory medicine most often administered as an intramuscular or intravenous injection for the short-term treatment of moderate to severe pain.

Patients who received ROX-888 -- ROXRO PHARMA's intranasal ketorolac -- required significantly less morphine following surgery than patients who had access only to morphine, data from the Phase 2 study showed.